SEP 2020

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/1282091

Contents of this Issue


Page 57 of 58

XIA-1390898 References: 1. US Food and Drug Administration. Code of Federal Regulations, Title 21, Volume 5 (21CFR349). Accessed April 17, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=349&showFR=1 2. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575-628. 3. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020. SHE MAY NEED MORE THAN ARTIFICIAL TEARS TO DISRUPT INFLAMMATION IN DRY EYE DISEASE 1,2 Her eyes deserve a change. Choose twice-daily Xiidra for lasting relief that can start as early as 2 weeks. 3 * † Important Safety Information (cont) • Inclinicaltrials,themostcommonadversereactionsreportedin5-25%ofpatientswereinstillationsite irritation,dysgeusiaandreducedvisualacuity.Otheradversereactionsreportedin1%to5%ofthepatients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis. • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface. • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration. • Safetyandefficacyinpediatricpatientsbelowtheageof17yearshavenotbeenestablished. For additional safety information about XIIDRA ® , please refer to the brief summary of Full Prescribing Information on adjacent page. XIIDRA, the XIIDRA logo and ii are registered trademarks of Novartis AG. © 2020 Novartis 6/20

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - SEP 2020